Company: NDRA
Filing Date: 2025-10-30
Form Type: 424B5
Source: 0001213900-25-103705
Chunk: 0

Company: ENDRA Life Sciences Inc.
Filing Date: 2025-10-30
Form: 424B5
Chunk 0
---
| PROSPECTUS SUPPLEMENT               | Filed pursuant to Rule 424(b)(5) |
| (to Prospectus dated April 3, 2024) | Registration No. 333-277058      |

<div align='center'>ENDRA Life Sciences Inc.

$1,750,000

Common Stock</div>

ENDRA Life Sciences Inc. has entered into an At-The-Market
Issuance Sales Agreement (the “Sales Agreement”) with Lucid Capital Markets, LLC (the “Sales Agent”) relating
to the offer and sale of up to $1,750,000 of our common stock, par value $0.0001 per share (the “common stock”), offered by
this prospectus supplement and the accompanying prospectus.

Sales of our common stock, if any, under this
prospectus supplement and the accompanying prospectus may be made in transactions that are deemed to be “at-the-market” offerings
as defined in Rule 415 under the Securities Act of 1933, as amended (the “Securities Act”), including sales made directly
on or through the Nasdaq Capital Market (“Nasdaq”), the trading market for our common stock, or any other trading market in
the United States for our common stock, sales made to or through a market maker other than on an exchange, directly to the Sales Agent
as principal for its own account in negotiated transactions at market prices prevailing at the time of sale or at prices related to such
prevailing market prices, in privately negotiated transactions, in block trades, or through a combination of any such methods of sale.
The Sales Agent will act as sales agent on a commercially reasonable efforts basis consistent with its normal trading and sales practices.
There is no arrangement for funds to be received in any escrow, trust or similar arrangement.

We will pay the Sales Agent a commission equal
to 3.0% of the gross sales price per share of common stock issued by us and sold through the Sales Agent as our sales agent under the
Sales Agreement. In connection with the sale of the common stock on our behalf, the Sales Agent will be deemed to be an “underwriter”
within the meaning of the Securities Act and the compensation of the Sales Agent will be deemed to be underwriting commissions or discounts.

Our common stock trades on the Nasdaq Capital
Market under the symbol “NDRA.” On October 28, 2025, the last reported sale price for our common stock was $5.28 per share.

As